Lineage Cell Therapeutics, Inc. (AMEX: LCTX) last traded at $1.08, up 0.00% on the session. The quote above updates while this page is open; the figures below are drawn from Lineage Cell Therapeutics, Inc.’s own filings and are restated only when a new one is published.
Lineage Cell Therapeutics, Inc. trades on AMEX under the ticker LCTX. Its market capitalisation is $273.14 million.
Valuation measures for Lineage Cell Therapeutics, Inc., derived from the latest quote and its most recent SEC filing.
| Market cap | $273.14M |
|---|---|
| Enterprise value | $282.21M |
| Price / sales | 20.88 |
| Price / book | 4.48 |
| Beta | 1.43 |
Trailing-twelve-month figures tagged in Lineage Cell Therapeutics, Inc.'s XBRL filings with the SEC.
| Revenue (TTM) | $13.08M |
|---|---|
| Net income (TTM) | -$32.26M |
| Operating margin | -205.23% |
| Return on equity | -52.96% |
| Cash | $37.35M |
Range and volume for LCTX over the past 52 weeks.
| 52-week high | $2.09 |
|---|---|
| 52-week low | $1.00 |
| Volume | 709.5K |
| Average volume | 1.36M |
| Previous close | $1.08 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.